For example, DTBRE23078 is a Phase 3 randomized-controlled trial investigating Sacituzumab Govitecan versus physician-selected treatment in HR +/HER2- advanced breast cancer [19]. This evidence concerns the gene ERBB2 and breast carcinoma.